Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-12-26
2006-12-26
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S450000, C514S012200, C514S013800, C530S326000
Reexamination Certificate
active
07153490
ABSTRACT:
Liposomes encapsulating anticancerous drugs and the use thereof in the treatment of malignant tumors. The liposomes are coated with a lipopeptide composed of three substructures: a lipid fragment, an active oligopeptide and an oligopeptide spacer between the other two fragments. Applicable in intravenous administration for treatment of malignant tumors.
REFERENCES:
patent: 5605703 (1997-02-01), Lambiez et al.
patent: 0274174 (1988-07-01), None
patent: 85/00968 (1985-03-01), None
patent: 86/04232 (1986-07-01), None
patent: 92/02208 (1992-02-01), None
patent: 98/16198 (1998-04-01), None
Manning et al. Review: Stability of protein pharmaceuticals. Pharm. Res., 6(11), 903-17, 1989.
D.S. Grandt, et al., “Interaction of Endothelial Cells With A Laminin A Chain Peptide (SIKVAV) in Vitro and Induction of Angiogenic Behavior in Vivo”,Journal of Cellular Physiology, vol. 153, No. 3, 1991, pp. 614-625.
International Search Report PCT/ES01/00367.
T.M. Allen et al., “Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues,” Biochimica et Biophysica Acta. 981:27-35 (1989).
T.M. Allen et al., “Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size,” Biochimica et Biophysica Acta. 1061:56-64 (1991).
S. Dedhar et al., “Alterations in Integrin Receptor Expression on Chemically Transformed Human Cells: Specific Enhancement of Laminin and Collagen Receptor Complexes,” The Journal of Cell Biology 110:481-189 (1990).
E.A. Forssen et al., Proc. Natl. Acad. Sci. USA 78:1873-1877 (1981).
E.A. Forssen et al., “Improved Therapeutic Benefits of Doxorubicin by Entrapment in Anionic Liposomes,” Cancer Research 43:546-550 (1983).
E.A. Forssen et al., “Attenuation of Dermal Toxicity of Doxorubicin by Liposome Encapsulation,” Cancer Treatment Reports 67:481-484 (1983).
A. Gabizon et al., “Liposomes asin vivoCarriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice,” Cancer Research 42:4734-4739 (1982).
A. Gabizon et al., “Enhancement of Adriamycin Delivery to Liver Metastatic Cells with Increased Tumoricidal Effect Using Liposomes as Drug Carriers,” Cancer Research 43:4730-4735 (1983).
A. Gabizon et al., “Superior Therapeutic Activity of Liposome-Associated Adriamycin in a Murine Metastatic Tumour Model,” Br. J. Cancer 51:681-689 (1985).
A. Gabizon et al., “Comparative Long-Term Study of the Toxicities of Free and Liposome-Associates Doxorubicin in Mice After Intravenous Administration,” J. Natl. Cancer Inst. 77(2):459-467 (1986).
E. Mayhew et al., “Effect of Liposome Entrapped Chemotherapeutic Agents on Mouse Primary and Metastatic Tumors,” Biol. Cell 47:81-85 (1983).
F. Olson et al., “Characterization, Toxicity and Therapeutic Efficacy of Adriamycin Encapsulated in Liposomes,” Eur. J. Cancer Clin. Oncol. 18(2):167-176 (1982).
A. Rahman et al., “Liposomal Protection of Adriamycin-Induced Carciotoxicity in Mice,” Cancer Research 40:1532-1537 (1980).
A. Rahman et al., “Pharmacological, Toxicological, and Therapeutic Evaluation in Mice of Doxorubicin Entrapped in Cardiolipin Liposomes,” Cancer Research 45:796-803 (1985).
C. Storm et al., “Influence of Lipid Composition on the Antitumor Activity Exerted by Doxorubicin-Containing Liposomes in a Rat Solid Tumor Model,” Cancer Research 47:3366-3372 (1987).
Q.G.C.M. van Hoesel et al., “Reduced Cardiotoxicity and Nephrotoxicity with Preservation of Antitumor Activity of Doxorubicin Entrapped in Stable Liposomes,” Cancer Research 44:3698-3705 (1984).
R.C. Young et al., “The Anthracycline Antineoplastic Drugs,” N. Eng. J. Med. 305(3):139-153 (1981).
T.M. Allen et al., “Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo,” Biochimica et Biophysica Acta 1066:29-36 (1991).
G. Blume et al., “Liposomes for the sustained drug release in vivo,” Biochimica et Biophysica Acta 1029:91-97 (1990).
E.G. Mayhew et al., “Effects of Liposome-Entrapped Doxorubicin on Liver Metastases of Mouse Colon Carcinomas 26 and 38,” JNCI 78(4):707-713 (1987).
A. Mori et al., “Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1on the circulation time of liposomes and on the target binding of immunoliposomes in vivo,” FEBS 284(2):263-266 (1991).
A. Rahman et al., “Antitumor and toxicity evaluation of free doxorubicin and dosorubicin entrapped in cardiolipin liposomes,” Cancer Chemother. Pharmacol. 16:22-27 (1986).
Fabra Fres Angels
Garces Garces Josep
Parente Dueña Antonio
Polo Trasancos María Dolores
Pons Lambiez Ferran
Audet Maury
Lipotec, SA
Ostrolenk Faber Gerb & Soffen, LLP
Tsang Cecilia J.
LandOfFree
Liposomes encapsulating anticancer drugs and use thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomes encapsulating anticancer drugs and use thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomes encapsulating anticancer drugs and use thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719457